What is the share price of Transgene Biotek Ltd (TRABI) today?
The share price of TRABI as on 29th April 2025 is ₹3.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Transgene Biotek Ltd (TRABI) share?
The past returns of Transgene Biotek Ltd (TRABI) share are- Past 1 week: -2.55%
- Past 1 month: 14.71%
- Past 3 months: -20.04%
- Past 6 months: -45.01%
- Past 1 year: -49.05%
- Past 3 years: 6.23%
- Past 5 years: 0.27%
What are the peers or stocks similar to Transgene Biotek Ltd (TRABI)?
The peers or stocks similar to Transgene Biotek Ltd (TRABI) include:What is the market cap of Transgene Biotek Ltd (TRABI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Transgene Biotek Ltd (TRABI) is ₹28.41 Cr as of 29th April 2025.What is the 52 week high and low of Transgene Biotek Ltd (TRABI) share?
The 52-week high of Transgene Biotek Ltd (TRABI) is ₹10.84 and the 52-week low is ₹3.22.What is the PE and PB ratio of Transgene Biotek Ltd (TRABI) stock?
The P/E (price-to-earnings) ratio of Transgene Biotek Ltd (TRABI) is -43.05. The P/B (price-to-book) ratio is 2.65.Which sector does Transgene Biotek Ltd (TRABI) belong to?
Transgene Biotek Ltd (TRABI) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Transgene Biotek Ltd (TRABI) shares?
You can directly buy Transgene Biotek Ltd (TRABI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Transgene Biotek Ltd
TRABI Share Price
3.751.83% (-0.07)
TRABI Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
TRABI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -123.54 | 2.65 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.81 | 6.38 | 0.53% |
TRABI Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
TRABI Company Profile
Transgene Biotek is a biotechnology company which operates transgene medical centers. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics
TRABI Similar Stocks (Peers)
Compare with peersBIOCON
PE Ratio
37.36
1Y Return
4.15%
Buy Reco %
73.33
ONESOURCE
PE Ratio
-46.40
1Y Return
7.26%
Buy Reco %
—
SAILIFE
PE Ratio
179.80
1Y Return
6.58%
Buy Reco %
66.67
PANACEABIO
PE Ratio
-2,951.81
1Y Return
295.13%
Buy Reco %
—
HESTERBIO
PE Ratio
82.82
1Y Return
13.13%
Buy Reco %
—
TRABI Forecasts
Price
Revenue
Earnings
TRABI Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeTRABI Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeTRABI Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeTRABI
Income
Balance Sheet
Cash Flow
Annual Normal View
TRABI Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.35 | 0.94 | 7.49 | 2.11 | 0.18 | 0.44 | 0.30 | 0.24 | 0.41 | 1.02 | ||||||||||
Raw Materials | 0.00 | 0.00 | 0.03 | 0.03 | 0.01 | 0.06 | -0.05 | 0.07 | 0.00 | 1.08 | ||||||||||
| Power & Fuel Cost | 0.10 | 0.12 | 0.06 | 0.06 | 0.16 | 0.01 | 0.01 | 0.01 | 0.00 | |||||||||||
| Employee Cost | 0.68 | 0.55 | 0.33 | 0.25 | 0.29 | 0.25 | 0.29 | 0.30 | 0.31 | |||||||||||
| Selling & Administrative Expenses | 0.47 | 0.20 | 0.25 | 0.35 | 0.37 | 0.27 | 0.27 | 0.27 | 0.48 | |||||||||||
| Operating & Other expenses | 0.06 | 1.97 | 1.54 | 0.05 | 0.03 | 0.10 | 0.02 | 0.02 | 0.05 | |||||||||||
EBITDA | -0.96 | -1.90 | 5.28 | 1.37 | -0.68 | -0.25 | -0.24 | -0.43 | -0.43 | -0.06 | ||||||||||
| Depreciation/Amortization | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.08 | ||||||||||
| PBIT | -21.46 | -19.43 | -4.61 | -8.52 | -10.58 | -10.16 | -10.16 | -5.38 | -0.52 | -0.14 | ||||||||||
| Interest & Other Items | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.09 | ||||||||||
| PBT | -21.53 | -19.86 | -5.64 | -8.78 | -10.96 | -10.43 | -10.39 | -6.00 | -0.66 | -0.23 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -21.53 | -19.86 | -6.43 | -8.78 | -10.96 | -10.43 | -10.39 | -6.00 | -0.66 | -0.23 | ||||||||||
| EPS | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.03 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
TRABI Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFTRABI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Transgene Biotek Ltd | -43.05 | 2.65 | — |
| Biocon Ltd | 37.36 | 1.51 | 0.16% |
| Onesource Specialty Pharma Ltd | -46.40 | 45.86 | — |
| Sai Life Sciences Ltd | 179.80 | 15.27 | — |
TRABI Stock Price Comparison
Compare TRABI with any stock or ETFCompare TRABI with any stock or ETF
TRABI
TRABI Shareholdings
TRABI Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.96%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
TRABI Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.26%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
TRABI Shareholding Pattern
TRABI Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing TRABI stock
Looks like this stock is not in any smallcase yet.
TRABI Events
TRABI Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
TRABI has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
TRABI Dividends
Hmm, looks like data is unavailable here. Please come back after some timeTRABI Stock News & Opinions
Articles & Videos
Corporate
Transgene Biotek announces board meeting date
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 7 May 2025.Powered by Capital Market - Live
1 day agoCapital Market - Live
Earnings
Transgene Biotek reports consolidated net loss of Rs 0.09 crore in the December 2024 quarter
Net Loss of Transgene Biotek reported to Rs 0.09 crore in the quarter ended December 2024 as against net loss of Rs 0.12 crore during the previous quarter ended December 2023. Sales rose 60.00% to Rs 0.08 crore in the quarter ended December 2024 as against Rs 0.05 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales0.080.05 60 OPM %-112.50-200.00 - PBDT-0.07-0.10 30 PBT-0.09-0.12 25 NP-0.09-0.12 25 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Transgene Biotek declare Quarterly Result
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Transgene Biotek reports consolidated net loss of Rs 0.07 crore in the September 2024 quarter
Net Loss of Transgene Biotek reported to Rs 0.07 crore in the quarter ended September 2024 as against net loss of Rs 0.13 crore during the previous quarter ended September 2023. Sales rose 20.00% to Rs 0.06 crore in the quarter ended September 2024 as against Rs 0.05 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales0.060.05 20 OPM %-116.67-240.00 - PBDT-0.05-0.11 55 PBT-0.07-0.13 46 NP-0.07-0.13 46 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Transgene Biotek to announce Quarterly Result
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Transgene Biotek reports consolidated net profit of Rs 0.20 crore in the June 2024 quarter
Net profit of Transgene Biotek reported to Rs 0.20 crore in the quarter ended June 2024 as against net loss of Rs 0.13 crore during the previous quarter ended June 2023. Sales declined 50.00% to Rs 0.05 crore in the quarter ended June 2024 as against Rs 0.10 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales0.050.10 -50 OPM %-820.00-120.00 - PBDT0.22-0.11 LP PBT0.20-0.13 LP NP0.20-0.13 LP Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Transgene Biotek to hold board meeting
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Transgene Biotek reports consolidated net loss of Rs 2.60 crore in the September 2021 quarter
3 years agoBusiness Standard
Transgene Biotek reports consolidated net loss of Rs 2.61 crore in the June 2021 quarter
3 years agoBusiness Standard
Transgene Biotek reports consolidated net loss of Rs 2.61 crore in the March 2021 quarter
3 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of -27.94%, vs industry avg of 19.04%
Over the last 5 years, market share decreased from 0.03% to 0%